Aberdare Ventures

Gravie, Inc. is a health insurance platform based in Minneapolis, Minnesota, that provides health insurance plans for individuals, families, and employers. Established in 2013, Gravie enables users to compare insurance options available through government-run marketplaces as well as directly from insurance companies. The company specializes in designing tailored benefits plans for employees, managing payments, and offering year-round support. Its services include Gravie Care, which allows individuals to shop for their benefits, and it utilizes a mobile application and website for ease of access. Gravie's innovative approach includes a defined contribution model, allowing employers to set fixed annual budgets for health benefits while providing tools for effective cost management. The platform also facilitates a better understanding of healthcare expenses through detailed price comparisons and information on co-pays, co-insurance, and applicable tax credits.

Autonomic Technologies, Inc. is a medical device company that specializes in developing and commercializing innovative therapies for autonomic disorders, with a particular emphasis on severe headaches. Founded in 2007 and headquartered in Mountain View, California, the company has additional offices in Germany and Switzerland. Its flagship product, the ATI Neurostimulation System, is a miniaturized, battery-less microstimulator designed to deliver low-level energy directly to the sphenopalatine ganglion (SPG) to effectively treat chronic cluster headaches. This technology aims to set a new standard in the management of severe headaches and migraines, providing patients with a safe and effective treatment option.

Jiff, Inc. is a technology company specializing in digital health applications and platforms designed for the healthcare industry. Established in 2010 and headquartered in Mountain View, California, Jiff provides a HIPAA-compliant environment where consumers and healthcare professionals can create personalized communities of care. The company's offerings include JiffPad, an iPad educational platform that enhances doctor-patient communication by transforming discussions and imagery into shareable videos, allowing patients to engage from home. Additionally, JiffPad connects medical professionals to a network of leaders and organizations through JiffTalks. The company aims to improve employee health engagement by linking company benefits with healthy behaviors, utilizing familiar wearables and applications. Jiff has formed strategic alliances with firms such as Towers Watson & Co. and Mercer, and it operates as a subsidiary of Castlight Health, Inc. as of 2017.

Autonomic Technologies, Inc. is a medical device company that specializes in developing and commercializing innovative therapies for autonomic disorders, with a particular emphasis on severe headaches. Founded in 2007 and headquartered in Mountain View, California, the company has additional offices in Germany and Switzerland. Its flagship product, the ATI Neurostimulation System, is a miniaturized, battery-less microstimulator designed to deliver low-level energy directly to the sphenopalatine ganglion (SPG) to effectively treat chronic cluster headaches. This technology aims to set a new standard in the management of severe headaches and migraines, providing patients with a safe and effective treatment option.

Gravie, Inc. is a health insurance platform based in Minneapolis, Minnesota, that provides health insurance plans for individuals, families, and employers. Established in 2013, Gravie enables users to compare insurance options available through government-run marketplaces as well as directly from insurance companies. The company specializes in designing tailored benefits plans for employees, managing payments, and offering year-round support. Its services include Gravie Care, which allows individuals to shop for their benefits, and it utilizes a mobile application and website for ease of access. Gravie's innovative approach includes a defined contribution model, allowing employers to set fixed annual budgets for health benefits while providing tools for effective cost management. The platform also facilitates a better understanding of healthcare expenses through detailed price comparisons and information on co-pays, co-insurance, and applicable tax credits.

goBalto, Inc. is a cloud-based software provider that focuses on enhancing the efficiency of clinical trials in the pharmaceutical, biotechnology, and medical device sectors. Founded in 2008 and headquartered in San Francisco, California, the company offers a suite of products designed to streamline the clinical research process. Their flagship solutions include Select, which assists in identifying suitable sites and target populations through data analysis; Activate, which facilitates the rapid initiation of studies by sponsors, contract research organizations, and investigative sites; and Analyze, which delivers operational insights and status updates to improve project management. GoBalto's offerings also encompass operational performance, oversight, risk management, business intelligence, and compliance solutions. The company operates additional offices in Singapore and King of Prussia, Pennsylvania, and is a subsidiary of Oracle Corporation.

Jiff, Inc. is a technology company specializing in digital health applications and platforms designed for the healthcare industry. Established in 2010 and headquartered in Mountain View, California, Jiff provides a HIPAA-compliant environment where consumers and healthcare professionals can create personalized communities of care. The company's offerings include JiffPad, an iPad educational platform that enhances doctor-patient communication by transforming discussions and imagery into shareable videos, allowing patients to engage from home. Additionally, JiffPad connects medical professionals to a network of leaders and organizations through JiffTalks. The company aims to improve employee health engagement by linking company benefits with healthy behaviors, utilizing familiar wearables and applications. Jiff has formed strategic alliances with firms such as Towers Watson & Co. and Mercer, and it operates as a subsidiary of Castlight Health, Inc. as of 2017.

Gravie, Inc. is a health insurance platform based in Minneapolis, Minnesota, that provides health insurance plans for individuals, families, and employers. Established in 2013, Gravie enables users to compare insurance options available through government-run marketplaces as well as directly from insurance companies. The company specializes in designing tailored benefits plans for employees, managing payments, and offering year-round support. Its services include Gravie Care, which allows individuals to shop for their benefits, and it utilizes a mobile application and website for ease of access. Gravie's innovative approach includes a defined contribution model, allowing employers to set fixed annual budgets for health benefits while providing tools for effective cost management. The platform also facilitates a better understanding of healthcare expenses through detailed price comparisons and information on co-pays, co-insurance, and applicable tax credits.

goBalto, Inc. is a cloud-based software provider that focuses on enhancing the efficiency of clinical trials in the pharmaceutical, biotechnology, and medical device sectors. Founded in 2008 and headquartered in San Francisco, California, the company offers a suite of products designed to streamline the clinical research process. Their flagship solutions include Select, which assists in identifying suitable sites and target populations through data analysis; Activate, which facilitates the rapid initiation of studies by sponsors, contract research organizations, and investigative sites; and Analyze, which delivers operational insights and status updates to improve project management. GoBalto's offerings also encompass operational performance, oversight, risk management, business intelligence, and compliance solutions. The company operates additional offices in Singapore and King of Prussia, Pennsylvania, and is a subsidiary of Oracle Corporation.

Advance Medical is a leading telemedicine provider that specializes in delivering expert medical opinions and concierge-level medical advice to patients worldwide. Established in 1999, the company operates offices across the U.S., Europe, Asia, and South America. Advance Medical uniquely focuses on connecting patients with board-certified physicians who provide personalized consultations via phone or video, ensuring comprehensive medical guidance for various health issues. The services offered facilitate accurate diagnoses, tailored treatment plans, and recommendations for top healthcare facilities, fostering strong relationships between patients and medical professionals.

Adavium Medical is a medical equipment and diagnostics company based in São Paulo, Brazil, established in 2011. The company focuses on commercializing an innovative portfolio of medical devices and diagnostic products, representing leading international manufacturers. With a workforce of over 300 employees, Adavium Medical operates a fully-integrated commercial platform that adheres to high standards. It boasts the largest customer base in Brazil, serving more than 2,500 clients in both premium and long-tail segments of the medical equipment and diagnostics market. This extensive reach significantly surpasses that of typical distributors and multinational companies in the region, positioning Adavium Medical as a key player in a fragmented industry.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

Cervel Neurotech, Inc., based in San Mateo, California, is a private medical device company that specializes in non-invasive deep brain neuro-modulation. Founded in 2008 by M. Bret Schneider, MD, David J. Mishelevich, MD, PhD, and entrepreneur Michael J. Partsch, the company has developed a proprietary technology that utilizes repetitive transcranial magnetic stimulation (rTMS) to modulate brain function through magnetic fields that induce electrical currents. This innovative approach, known as Steerable TMS, allows for targeted stimulation of specific brain areas associated with psychiatric and neurological disorders, minimizing unintended effects and facilitating quicker patient treatment initiation. Cervel Neurotech's technology is based on licensed research from Stanford University and was acquired by Rio Grande Neurosciences in 2015.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

goBalto, Inc. is a cloud-based software provider that focuses on enhancing the efficiency of clinical trials in the pharmaceutical, biotechnology, and medical device sectors. Founded in 2008 and headquartered in San Francisco, California, the company offers a suite of products designed to streamline the clinical research process. Their flagship solutions include Select, which assists in identifying suitable sites and target populations through data analysis; Activate, which facilitates the rapid initiation of studies by sponsors, contract research organizations, and investigative sites; and Analyze, which delivers operational insights and status updates to improve project management. GoBalto's offerings also encompass operational performance, oversight, risk management, business intelligence, and compliance solutions. The company operates additional offices in Singapore and King of Prussia, Pennsylvania, and is a subsidiary of Oracle Corporation.

MC10, Inc. specializes in the development and sale of wearable medical sensors designed to collect clinical-grade biometric and physiological data, primarily for use in clinical trials. Founded in 2008 and based in Lexington, Massachusetts, the company offers a range of products, including BioStamp nPoint, which processes raw data into clinical metrics such as vital signs and sleep patterns; Kintinuum, an orthopedic rehabilitation device; WiSP, a cardiac monitoring solution; and BioStampMD, a conformable sensor for gathering both objective and subjective health data. MC10 focuses on creating flexible, lightweight electronics that conform to the human body, allowing for discreet and comfortable data collection in various settings. Its proprietary BioStamp system enhances the ability to gather real-world data on muscle activation and movement, thereby advancing digital healthcare services across multiple sectors, including sports and military applications.

Wello is an online platform offering live fitness training over two-way video. It provides an affordable and easy way for its users to workout with a live fitness professional of their choice. Its first product called 1-on-1 personal training was launched in 2012. In 2013, Wello completed the program at Rock Health and became part of a prolific network of the best digital health companies in the country. It matches clients with the right Wello-vetted trainer and workout program for them, provides seamless scheduling and payment, and establishes the live video connection for the workout to take place. Wello was launched in 2011 by Stanford MBA students Ann Scott Plante and Leslie Silverglide. It is based in San Francisco, C.A.

Bluesight operates as a healthcare technology company specializing in supply chain optimization for pharmaceuticals. It offers Medication Intelligence solutions that provide real-time analytics across the entire medication lifecycle, enhancing efficiency, reducing risks, and improving patient safety within hospitals. The core product is an inventory management platform that automates pharmacy kit processing and medication tracking, replacing manual processes to increase operational efficiency and medication visibility.

RxAnte Inc. is a healthcare analytics company based in Portland, Maine, that specializes in predictive analytics and targeted clinical programs aimed at improving medication adherence and prescribing practices. Founded in 2008, RxAnte's platform enables health plans to predict individual patients' medication adherence, allowing for tailored interventions that enhance patient outcomes. A key feature of their offerings is the Mosaic Pharmacy Service, which focuses on providing an improved pharmacy experience for complex and vulnerable members while collaborating with prescribers and caregivers. This approach not only simplifies medication regimens but also aims to make them safer and more affordable, ultimately enhancing clinical quality and reducing overall healthcare costs. As of January 2014, RxAnte operates as a subsidiary of Millennium Laboratories, Inc.

Jiff, Inc. is a technology company specializing in digital health applications and platforms designed for the healthcare industry. Established in 2010 and headquartered in Mountain View, California, Jiff provides a HIPAA-compliant environment where consumers and healthcare professionals can create personalized communities of care. The company's offerings include JiffPad, an iPad educational platform that enhances doctor-patient communication by transforming discussions and imagery into shareable videos, allowing patients to engage from home. Additionally, JiffPad connects medical professionals to a network of leaders and organizations through JiffTalks. The company aims to improve employee health engagement by linking company benefits with healthy behaviors, utilizing familiar wearables and applications. Jiff has formed strategic alliances with firms such as Towers Watson & Co. and Mercer, and it operates as a subsidiary of Castlight Health, Inc. as of 2017.

Viracta Therapeutics, Inc. is a clinical-stage drug development company based in Cardiff, California, that specializes in precision oncology focused on virus-associated malignancies. The company utilizes a viral activation therapy platform to develop treatments for cancers linked to the Epstein-Barr Virus (EBV) and other virus-related diseases. Its lead investigational drug, nanatinostat, is being evaluated in combination with the antiviral valganciclovir as a potential oral therapy for EBV-positive lymphoma, including post-transplant lymphoproliferative disorder, plasmablastic lymphoma, and angioimmunoblastic T cell lymphoma. Viracta is also exploring the application of this approach to other EBV-associated conditions, such as nasopharyngeal carcinoma and gastric carcinoma. Founded in 2007 and rebranded from HemaQuest Pharmaceuticals in 2015, Viracta Therapeutics is actively conducting multiple clinical trials to advance its therapeutic candidates.

MC10, Inc. specializes in the development and sale of wearable medical sensors designed to collect clinical-grade biometric and physiological data, primarily for use in clinical trials. Founded in 2008 and based in Lexington, Massachusetts, the company offers a range of products, including BioStamp nPoint, which processes raw data into clinical metrics such as vital signs and sleep patterns; Kintinuum, an orthopedic rehabilitation device; WiSP, a cardiac monitoring solution; and BioStampMD, a conformable sensor for gathering both objective and subjective health data. MC10 focuses on creating flexible, lightweight electronics that conform to the human body, allowing for discreet and comfortable data collection in various settings. Its proprietary BioStamp system enhances the ability to gather real-world data on muscle activation and movement, thereby advancing digital healthcare services across multiple sectors, including sports and military applications.

Omada Health, Inc. is a digital healthcare company that specializes in developing online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, California, with an additional office in Atlanta, Georgia, Omada focuses on preventing conditions such as prediabetes, diabetes, hypertension, and heart disease. The company provides personalized digital health programs that cater to the unique needs of individuals, utilizing professional health coaching, connected health devices, and real-time data to facilitate meaningful health improvements. Omada is recognized as the largest provider of the National Diabetes Prevention Program, empowering individuals to engage actively in their health and achieve sustainable lifestyle changes. The platform also addresses behavioral health issues, including anxiety and depression, further supporting individuals in their overall wellness journey.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

Autonomic Technologies, Inc. is a medical device company that specializes in developing and commercializing innovative therapies for autonomic disorders, with a particular emphasis on severe headaches. Founded in 2007 and headquartered in Mountain View, California, the company has additional offices in Germany and Switzerland. Its flagship product, the ATI Neurostimulation System, is a miniaturized, battery-less microstimulator designed to deliver low-level energy directly to the sphenopalatine ganglion (SPG) to effectively treat chronic cluster headaches. This technology aims to set a new standard in the management of severe headaches and migraines, providing patients with a safe and effective treatment option.

NxThera, Inc. is a medical technology company based in Maple Grove, Minnesota, established in 2008 and currently a subsidiary of Boston Scientific Corporation. The company specializes in convective water vapor energy technology aimed at treating endourological conditions, particularly benign prostatic hyperplasia (BPH), which affects over 32 million men in the United States. NxThera's innovative platform employs a minimally invasive vapor therapy that converts sterile water into thermal energy delivered to prostate tissue, providing an effective treatment option for patients suffering from urologic conditions, including prostate and kidney cancer. This approach aims to enhance urinary flow and improve overall patient quality of life while minimizing side effects commonly associated with traditional treatments.

Nevro Corporation is a global medical device company specializing in innovative solutions for chronic pain management. Its primary product is the Senza spinal cord stimulation (SCS) system, which employs proprietary HF10 therapy to deliver evidence-based neuromodulation treatment. The Senza system consists of implantable components controlled by patients and managed by healthcare professionals using specialized software. Nevro generates a significant portion of its revenue in the United States.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

Posit Science Corporation, founded in 2002 and headquartered in San Francisco, California, specializes in brain training software designed to enhance cognitive performance. The company offers clinically proven exercises through its website that focus on improving brain speed, attention, and memory. These programs leverage advances in the science of brain plasticity, which is the brain's capacity to adapt and change throughout life. By targeting the speed and accuracy of information processing, Posit Science aims to help individuals maximize their cognitive abilities and improve their performance in everyday activities. The company was previously known as Neuroscience Solutions Corporation before rebranding in January 2005.

Conatus Pharmaceuticals Inc. is a biotechnology company that specializes in the development of innovative therapeutics for the treatment of liver diseases. Founded in 2005 and headquartered in San Diego, California, the company is primarily focused on advancing treatments for conditions such as hepatitis C virus infection, portal hypertension, and liver fibrosis associated with nonalcoholic steatohepatitis. Its lead product candidate, Emricasan, is an orally active caspase protease inhibitor currently undergoing Phase IIb clinical trials. Additionally, Conatus is developing CTS-2090, an orally active inhibitor of caspase 1, which is in the preclinical stage aimed at addressing chronic diseases linked to inflammasome pathways. The company also has a collaboration agreement with Novartis to conduct multiple Phase IIb clinical trials. In May 2020, Conatus Pharmaceuticals was acquired by Histogen Inc. in a reverse merger transaction.

Vertiflex Inc. is a medical device company based in Carlsbad, California, specializing in minimally invasive solutions for lumbar spinal stenosis (LSS). Founded in 2005, the company develops advanced spinal surgery technologies, including the Superion Interspinous Spacer, a titanium implant designed to provide motion preservation and indirect decompression for patients with moderate lumbar spinal stenosis. Additionally, Vertiflex offers the Totalis Direct Decompression System, which includes specialized instruments for performing minimally invasive direct decompression of the lumbar spine. By focusing on procedures that minimize tissue trauma, Vertiflex aims to bridge the gap between conservative care and traditional spine surgery, enhancing treatment options for patients suffering from lumbar stenosis. As of June 2019, Vertiflex operates as a subsidiary of Boston Scientific Corporation.

Jiff, Inc. is a technology company specializing in digital health applications and platforms designed for the healthcare industry. Established in 2010 and headquartered in Mountain View, California, Jiff provides a HIPAA-compliant environment where consumers and healthcare professionals can create personalized communities of care. The company's offerings include JiffPad, an iPad educational platform that enhances doctor-patient communication by transforming discussions and imagery into shareable videos, allowing patients to engage from home. Additionally, JiffPad connects medical professionals to a network of leaders and organizations through JiffTalks. The company aims to improve employee health engagement by linking company benefits with healthy behaviors, utilizing familiar wearables and applications. Jiff has formed strategic alliances with firms such as Towers Watson & Co. and Mercer, and it operates as a subsidiary of Castlight Health, Inc. as of 2017.

EnteroMedics® Inc. is the developer of vBloc® neurometabolic therapy, delivered by a pacemaker-like device called the Maestro® Rechargeable System, a first-in-class weight loss treatment for obesity and obesity related risk factors, such as high blood pressure or high cholesterol levels. vBloc Therapy is a non-anatomy altering or restricting, reversible therapy that allows patients to safely lose weight by helping patients feel less hungry, reduce the amount of food eaten at a meal, and feel full longer in between meals.

Viracta Therapeutics, Inc. is a clinical-stage drug development company based in Cardiff, California, that specializes in precision oncology focused on virus-associated malignancies. The company utilizes a viral activation therapy platform to develop treatments for cancers linked to the Epstein-Barr Virus (EBV) and other virus-related diseases. Its lead investigational drug, nanatinostat, is being evaluated in combination with the antiviral valganciclovir as a potential oral therapy for EBV-positive lymphoma, including post-transplant lymphoproliferative disorder, plasmablastic lymphoma, and angioimmunoblastic T cell lymphoma. Viracta is also exploring the application of this approach to other EBV-associated conditions, such as nasopharyngeal carcinoma and gastric carcinoma. Founded in 2007 and rebranded from HemaQuest Pharmaceuticals in 2015, Viracta Therapeutics is actively conducting multiple clinical trials to advance its therapeutic candidates.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

Clovis Oncology, Inc. is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of anti-cancer agents in the United States, Europe, and other international markets. The company is known for its product Rubraca (rucaparib), an oral small molecule inhibitor designed to treat recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Additionally, Clovis is developing lucitanib, an oral inhibitor that targets various tyrosine kinase receptors associated with tumor growth. The company utilizes precision medicine and companion diagnostics to ensure that therapies are directed toward patients most likely to benefit from them. Clovis Oncology distributes its products primarily through specialty distributors and pharmacy providers. Founded in 2009 and headquartered in Boulder, Colorado, the company has established partnerships and licensing agreements with multiple pharmaceutical organizations, enhancing its ability to innovate within the oncology sector.

Posit Science Corporation, founded in 2002 and headquartered in San Francisco, California, specializes in brain training software designed to enhance cognitive performance. The company offers clinically proven exercises through its website that focus on improving brain speed, attention, and memory. These programs leverage advances in the science of brain plasticity, which is the brain's capacity to adapt and change throughout life. By targeting the speed and accuracy of information processing, Posit Science aims to help individuals maximize their cognitive abilities and improve their performance in everyday activities. The company was previously known as Neuroscience Solutions Corporation before rebranding in January 2005.

Mpex Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies to address the critical problem of antibiotic resistance, particularly concerning gram-negative bacteria. The company's internal development pipeline emphasizes the combination of proprietary formulations, pharmacokinetics/pharmacodynamics strategies, and novel potentiating agents with established antibiotics. This approach aims to counteract or inhibit the molecular mechanisms that contribute to antibiotic resistance. One of its key products, MP-376, is a proprietary formulation of levofloxacin designed as a maintenance therapy to prevent bacterial exacerbations in patients with cystic fibrosis and chronic obstructive pulmonary disease. Through these efforts, Mpex Pharmaceuticals seeks to provide effective solutions in the fight against resistant bacterial infections.

Anacor Pharmaceuticals is a biopharmaceutical company that specializes in discovering, developing, and commercializing small-molecule therapeutics based on its boron chemistry platform. The company is known for its marketed product, KERYDIN, a topical solution for treating onychomycosis of the toenails. Its lead candidate, crisaborole topical ointment, is currently in Phase III clinical trials aimed at addressing mild-to-moderate atopic dermatitis and psoriasis. Additionally, Anacor is developing AN3365, an antibiotic for infections caused by Gram-negative bacteria. The company has established collaboration agreements with various organizations to explore new treatments for diseases such as African trypanosomiasis, tuberculosis, and Chagas disease. Anacor Pharmaceuticals, which was incorporated in 2000 and is headquartered in Palo Alto, California, previously operated under the name AnaMax, Inc. It has been a subsidiary of Pfizer since June 2016.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

Nevro Corporation is a global medical device company specializing in innovative solutions for chronic pain management. Its primary product is the Senza spinal cord stimulation (SCS) system, which employs proprietary HF10 therapy to deliver evidence-based neuromodulation treatment. The Senza system consists of implantable components controlled by patients and managed by healthcare professionals using specialized software. Nevro generates a significant portion of its revenue in the United States.

Cervel Neurotech, Inc., based in San Mateo, California, is a private medical device company that specializes in non-invasive deep brain neuro-modulation. Founded in 2008 by M. Bret Schneider, MD, David J. Mishelevich, MD, PhD, and entrepreneur Michael J. Partsch, the company has developed a proprietary technology that utilizes repetitive transcranial magnetic stimulation (rTMS) to modulate brain function through magnetic fields that induce electrical currents. This innovative approach, known as Steerable TMS, allows for targeted stimulation of specific brain areas associated with psychiatric and neurological disorders, minimizing unintended effects and facilitating quicker patient treatment initiation. Cervel Neurotech's technology is based on licensed research from Stanford University and was acquired by Rio Grande Neurosciences in 2015.

Vertiflex Inc. is a medical device company based in Carlsbad, California, specializing in minimally invasive solutions for lumbar spinal stenosis (LSS). Founded in 2005, the company develops advanced spinal surgery technologies, including the Superion Interspinous Spacer, a titanium implant designed to provide motion preservation and indirect decompression for patients with moderate lumbar spinal stenosis. Additionally, Vertiflex offers the Totalis Direct Decompression System, which includes specialized instruments for performing minimally invasive direct decompression of the lumbar spine. By focusing on procedures that minimize tissue trauma, Vertiflex aims to bridge the gap between conservative care and traditional spine surgery, enhancing treatment options for patients suffering from lumbar stenosis. As of June 2019, Vertiflex operates as a subsidiary of Boston Scientific Corporation.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

Ablation Frontiers, Inc. is a medical device company located in Carlsbad, California, focused on developing solutions for individuals with atrial fibrillation (AF) and other cardiac arrhythmias. The company offers a range of products, including mapping and ablation catheters, as well as radiofrequency generators and accessories, aimed at assisting healthcare professionals in effectively treating these conditions. In 2006, Ablation Frontiers received CE Mark certification to market its catheter system and GENius™ Radiofrequency Generator in the European Union for treating supraventricular arrhythmias and atrioventricular node ablation. Currently, the company is conducting a clinical trial under a United States Food and Drug Administration investigational device exemption to seek approval for its catheter system to address permanent, long-standing, persistent, and chronic AF in the United States, where its products are not yet approved for marketing or sales.

Paracor Medical is a medical device company established in 1999 that specializes in developing innovative, technology-driven solutions for the treatment of heart failure. The company focuses on creating alternatives to traditional open chest surgery, aiming to alleviate the burden on patients with failing heart muscles. By employing a mechanical approach, Paracor Medical seeks to enhance the effectiveness of heart failure treatment while minimizing the invasiveness of procedures.

Conatus Pharmaceuticals Inc. is a biotechnology company that specializes in the development of innovative therapeutics for the treatment of liver diseases. Founded in 2005 and headquartered in San Diego, California, the company is primarily focused on advancing treatments for conditions such as hepatitis C virus infection, portal hypertension, and liver fibrosis associated with nonalcoholic steatohepatitis. Its lead product candidate, Emricasan, is an orally active caspase protease inhibitor currently undergoing Phase IIb clinical trials. Additionally, Conatus is developing CTS-2090, an orally active inhibitor of caspase 1, which is in the preclinical stage aimed at addressing chronic diseases linked to inflammasome pathways. The company also has a collaboration agreement with Novartis to conduct multiple Phase IIb clinical trials. In May 2020, Conatus Pharmaceuticals was acquired by Histogen Inc. in a reverse merger transaction.

Vertiflex Inc. is a medical device company based in Carlsbad, California, specializing in minimally invasive solutions for lumbar spinal stenosis (LSS). Founded in 2005, the company develops advanced spinal surgery technologies, including the Superion Interspinous Spacer, a titanium implant designed to provide motion preservation and indirect decompression for patients with moderate lumbar spinal stenosis. Additionally, Vertiflex offers the Totalis Direct Decompression System, which includes specialized instruments for performing minimally invasive direct decompression of the lumbar spine. By focusing on procedures that minimize tissue trauma, Vertiflex aims to bridge the gap between conservative care and traditional spine surgery, enhancing treatment options for patients suffering from lumbar stenosis. As of June 2019, Vertiflex operates as a subsidiary of Boston Scientific Corporation.

Sequoia Pharmaceuticals is a private, venture-capital funded company founded in 2002. They are engaged in the discovery and development of novel antiviral therapeutics with a focus on combating drug-resistant HIV and HCV. They are also developing pharmacokinetic enhancers to improve the exposure of co-administered therapeutics.

NBI Development is an implantable medical device company focused on the development of novel neuromodulation therapies. The company develops neuromodulation, the use of electrical impulses to manage activity in the nervous system.

Nevro Corporation is a global medical device company specializing in innovative solutions for chronic pain management. Its primary product is the Senza spinal cord stimulation (SCS) system, which employs proprietary HF10 therapy to deliver evidence-based neuromodulation treatment. The Senza system consists of implantable components controlled by patients and managed by healthcare professionals using specialized software. Nevro generates a significant portion of its revenue in the United States.

Posit Science Corporation, founded in 2002 and headquartered in San Francisco, California, specializes in brain training software designed to enhance cognitive performance. The company offers clinically proven exercises through its website that focus on improving brain speed, attention, and memory. These programs leverage advances in the science of brain plasticity, which is the brain's capacity to adapt and change throughout life. By targeting the speed and accuracy of information processing, Posit Science aims to help individuals maximize their cognitive abilities and improve their performance in everyday activities. The company was previously known as Neuroscience Solutions Corporation before rebranding in January 2005.

Kémia operates as a pharmaceutical company. The company discovers and develops small molecule therapeutics. It offers allosteric kinase inhibitors for the treatment of inflammatory diseases, such as rheumatoid arthritis, as well as for cardiovascular and metabolic conditions; and modulators of G protein-coupled receptors. The company specializes in the fields of medicinal and analytical chemistry, biology, pharmacology, pharmacokinetics, pharmacodynamics, and clinical development.

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Irvine, California, specializing in the development of innovative treatments for patients with disorders of the ear, nose, and throat, as well as for those undergoing organ or cellular transplantation and individuals with autoimmune and neurodegenerative diseases. The company’s lead product, OP0201, is a surfactant-based nasal aerosol designed for patients at risk for or suffering from otitis media. Additionally, Eledon has developed a foam-based drug delivery technology, OP0101 and OP0102, aimed at delivering medications to the ear, nose, and sinus cavities. The company also focuses on the CD40L pathway, with its main compound in development, tegoprubart, being an IgG1 anti-CD40L antibody that shows promise for treating autoimmune diseases and supporting organ transplants. Eledon Pharmaceuticals was formerly known as Novus Therapeutics, Inc. before its rebranding in January 2021.

KAI Pharmaceuticals is a drug discovery and development company focused on creating innovative therapeutics for cardiovascular disease, kidney disease, and pain management. The company's lead product candidate, KAI-9803, is undergoing a Phase 2b clinical trial aimed at evaluating its ability to reduce myocardial injury in patients experiencing heart attacks. Additionally, KAI is advancing its second core program, KAI-4169, which targets secondary hyperparathyroidism in kidney disease patients and is anticipated to enter human clinical trials. The company is also exploring pain management through its ongoing program, KAI-1678, currently in Phase 2a testing.

Mpex Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies to address the critical problem of antibiotic resistance, particularly concerning gram-negative bacteria. The company's internal development pipeline emphasizes the combination of proprietary formulations, pharmacokinetics/pharmacodynamics strategies, and novel potentiating agents with established antibiotics. This approach aims to counteract or inhibit the molecular mechanisms that contribute to antibiotic resistance. One of its key products, MP-376, is a proprietary formulation of levofloxacin designed as a maintenance therapy to prevent bacterial exacerbations in patients with cystic fibrosis and chronic obstructive pulmonary disease. Through these efforts, Mpex Pharmaceuticals seeks to provide effective solutions in the fight against resistant bacterial infections.

Vertiflex Inc. is a medical device company based in Carlsbad, California, specializing in minimally invasive solutions for lumbar spinal stenosis (LSS). Founded in 2005, the company develops advanced spinal surgery technologies, including the Superion Interspinous Spacer, a titanium implant designed to provide motion preservation and indirect decompression for patients with moderate lumbar spinal stenosis. Additionally, Vertiflex offers the Totalis Direct Decompression System, which includes specialized instruments for performing minimally invasive direct decompression of the lumbar spine. By focusing on procedures that minimize tissue trauma, Vertiflex aims to bridge the gap between conservative care and traditional spine surgery, enhancing treatment options for patients suffering from lumbar stenosis. As of June 2019, Vertiflex operates as a subsidiary of Boston Scientific Corporation.

Anacor Pharmaceuticals is a biopharmaceutical company that specializes in discovering, developing, and commercializing small-molecule therapeutics based on its boron chemistry platform. The company is known for its marketed product, KERYDIN, a topical solution for treating onychomycosis of the toenails. Its lead candidate, crisaborole topical ointment, is currently in Phase III clinical trials aimed at addressing mild-to-moderate atopic dermatitis and psoriasis. Additionally, Anacor is developing AN3365, an antibiotic for infections caused by Gram-negative bacteria. The company has established collaboration agreements with various organizations to explore new treatments for diseases such as African trypanosomiasis, tuberculosis, and Chagas disease. Anacor Pharmaceuticals, which was incorporated in 2000 and is headquartered in Palo Alto, California, previously operated under the name AnaMax, Inc. It has been a subsidiary of Pfizer since June 2016.

Sequoia Pharmaceuticals is a private, venture-capital funded company founded in 2002. They are engaged in the discovery and development of novel antiviral therapeutics with a focus on combating drug-resistant HIV and HCV. They are also developing pharmacokinetic enhancers to improve the exposure of co-administered therapeutics.

IDUN Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of human therapeutics to control apoptosis. Its products under Phase 2 and preclinical trials include drugs for liver disease, CNS diseases, inflammation, and cancer, as well as IDN-6556 for the treatment of liver diseases in patients infected with Hepatitis C virus. The company was founded in 1993 and is based in San Diego, California. As of July 30, 2010, IDUN Pharmaceuticals, Inc. operates as a subsidiary of Conatus Pharmaceuticals Inc.

Anacor Pharmaceuticals is a biopharmaceutical company that specializes in discovering, developing, and commercializing small-molecule therapeutics based on its boron chemistry platform. The company is known for its marketed product, KERYDIN, a topical solution for treating onychomycosis of the toenails. Its lead candidate, crisaborole topical ointment, is currently in Phase III clinical trials aimed at addressing mild-to-moderate atopic dermatitis and psoriasis. Additionally, Anacor is developing AN3365, an antibiotic for infections caused by Gram-negative bacteria. The company has established collaboration agreements with various organizations to explore new treatments for diseases such as African trypanosomiasis, tuberculosis, and Chagas disease. Anacor Pharmaceuticals, which was incorporated in 2000 and is headquartered in Palo Alto, California, previously operated under the name AnaMax, Inc. It has been a subsidiary of Pfizer since June 2016.

Anacor Pharmaceuticals is a biopharmaceutical company that specializes in discovering, developing, and commercializing small-molecule therapeutics based on its boron chemistry platform. The company is known for its marketed product, KERYDIN, a topical solution for treating onychomycosis of the toenails. Its lead candidate, crisaborole topical ointment, is currently in Phase III clinical trials aimed at addressing mild-to-moderate atopic dermatitis and psoriasis. Additionally, Anacor is developing AN3365, an antibiotic for infections caused by Gram-negative bacteria. The company has established collaboration agreements with various organizations to explore new treatments for diseases such as African trypanosomiasis, tuberculosis, and Chagas disease. Anacor Pharmaceuticals, which was incorporated in 2000 and is headquartered in Palo Alto, California, previously operated under the name AnaMax, Inc. It has been a subsidiary of Pfizer since June 2016.

Salmedix is an oncology drug development company with a commercial focus on the treatment of hematologic malignancies, or blood cancers. Its primary product, SDX-105, is marketed by healthcare professionals in Germany for the treatment of several types of blood cancers. Salmedix conducts Phase II clinical trials for SDX-105 in the U.S. and Canada. Its other clinical-stage product candidates, SDX-101 and SDX-102, each with significant prior human clinical experience, are also in Phase II development. Founded in 2000 by David Kabakoff, Salmedix is headquartered in San Diego, California.

Pharmion is a global biotech company that is dedicated to the hematology and oncology communities. We work in partnership with a network of scientific and clinical advisors to identify and develop products for global hematology and oncology markets. To expand each product's potential, we have established our own regulatory, development and sales and marketing organizations in the United States, Europe, and Australia, and we have developed a third-party distributor network to serve the hematology and oncology markets in 20 additional countries throughout the Middle East, Asia, and Latin America. The global capabilities within our sales, marketing and distribution organization distinguishes us from other companies of a similar size. With our international network we can reach physicians and their patients in more than 30 countries. With proven development and regulatory professionals and an experienced global commercialization team, we concentrate our resources on licensing, developing, and commercializing therapeutic products for the treatment of hematology and oncology patients. Through these efforts, we seek to provide greater therapeutic options to hematologists and oncologists with the ultimate goal of extending survival and improving patients’ quality of life.

Microbia an industrial biotechnology company, engages in the development, production, and commercialization of specialty ingredients and biomaterials utilizing fermentation technology. Its products include carotenoids, specialty ingredients, biopolymers, and other biomaterials. The company has a strategic alliance with Tate & Lyle Investments, Ltd. to develop and commercialize fermentation-derived renewable ingredients.

Alibris is an online marketplace that specializes in connecting independent sellers of new and used books, music, and movies with buyers around the world. Established in November 1998, the company has grown to become the largest independently owned and operated marketplace of its kind on the Internet, offering over 100 million items from thousands of sellers. Alibris focuses on providing access to a wide range of titles, including rare and collectible works, making it a valuable resource for enthusiasts and collectors. By facilitating direct transactions between sellers and buyers, Alibris fosters a community of individuals who share a passion for literature, music, and film.

CapitalThinking is a mortgage financial services company based in New York, founded in 1999. It specializes in providing fixed and flexible payment solutions to its customers through an online platform that facilitates applications and quotations. In addition to mortgage services, CapitalThinking offers application software tailored for the financial services industry, which includes compliance and risk management features designed for enterprise-wide credit and operational risk management. The company was acquired by CapitalStream in January 2004, further expanding its capabilities in the financial sector.